Fujairah Mountain Shooting Championship Returns for a New Edition in February 2025
9.9.2024 17:44:00 CEST | Business Wire | Press release
The Fujairah Shooting Club announces the important dates, side events, ambassadors and launch of the website of the second edition of Fujairah Mountain Shooting Championship
Following the resounding success of its inaugural edition in 2023, Fujairah Shooting Club has announced the return of the Fujairah Mountain Shooting Championship (FMSC) and the launch of the championship's official website for its second edition. The unparalleled and challenging sporting event will return in February 2025 and will be held under the patronage of His Highness Sheikh Mohammed bin Hamad Al Sharqi, Crown Prince of Fujairah.
The championship, which will run from February 1 to 8, 2025, in Dibba, Fujairah, UAE, will feature challenging layouts, exhilarating side events, and the chance to experience the natural beauty of the Emirate. The main championship, which will be held from February 5 to 8, will feature Super Sporting with 240 clays, a total prize of USD 300,000, and USD 50,000 for 100 flash clays.
The preliminary competitions of FMSC 2025 will be held from February 1 to 4 and will feature 50 clays of English Sporting with a total prize pool of USD 40,000 across four categories. The opening ceremony will be held on February 4, and the awards ceremony is scheduled for February 8, 2025.
The main championship will feature 24 stands, each equipped with six machines and presenting ten targets, including singles and doubles. Over the course of four days, 240 targets will be set, with 60 targets to be covered each day, and participants will be organised into six-man squads to compete throughout the event.
Saif Al Zahmi, Director, FMSC, said: “Held under the patronage of H.H. Sheikh Mohammed bin Hamad Al Sharqi, Crown Prince of Fujairah, FMSC draws inspiration from the rich hunting tradition of the region and celebrate its enduring heritage. We are delighted to announce the launch of the website, kicking off the most anticipated return of the event with many new additions in February 2025. Moreover, it is a unique sporting event with over AED 1,000,000 in prizes and a chance to experience the region's vibrant culture. The competition, along with exciting side events, promises an exhilarating experience while respecting the environment through the use of ammunition with 100% natural biodegradable wads and eco-friendly clay targets suitable for all ages.”
One of the highlights of the 2025 edition is side events such as Pool Shoots and English Sporting, which will be held from February 1 to 7. Additionally, the latest edition of the championship is organised with the support of the National Sporting Clays Association and the Clay Pigeon Shooting Association, features George Digweed MBE, a renowned English sport shooter and multiple world and European clay-shooting champion; Phil Gray and Saif Bin Futtais, an Emirati sport shooter and five-time Olympian, as ambassadors.
For more information, visit fmsc.ae.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909161040/en/
Contacts
Tarek Kamal El Dine, +971 50 8829649
Tarek Kamal El Dine, +971 50 8829649
tarek@cpo.fujairah.ae
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom